ARTICLE | Clinical News
MAT2501: Ph I data
March 31, 2017 5:14 AM UTC
Top-line data from a double-blind, placebo-controlled Phase I trial in 36 healthy volunteers showed that single ascending doses of oral MAT2501 were well tolerated with no serious adverse events repor...
BCIQ Company Profiles
BCIQ Target Profiles